CH0329023102 - Common Stock
AC IMMUNE SA
NASDAQ:ACIU (7/26/2024, 7:14:50 PM)
After market: 3.94 +0.03 (+0.77%)3.91
0 (0%)
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
AC IMMUNE SA
EPFL Innovation Park, Building B
Lausanne VAUD 1015
P: 41213459121
CEO: Andrea Pfeifer
Employees: 133
Website: https://www.acimmune.com/
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three...
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a...
Here you can normally see the latest stock twits on ACIU, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: